S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug may kill more tumor cells.
Colony-stimulating factors such as filgrastim may increase the number of immune cells found
in bone marrow or peripheral blood and may help a person's immune system recover from the
side effects of chemotherapy.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus
filgrastim in treating patients who have previously untreated extensive-stage small cell lung
cancer.